Skip to main content

Table 2 Treatment outcome according to treatment strategy

From: Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

  Initial endocrine therapy (N = 137) Initial chemotherapy (N = 78) Chemotherapy - endocrine therapy (N = 57)
Progression-free survival – mo
 Median 12.6 7.0 18.2
(95% CI) (9.0–16.2) (3.8–10.2) (14.3–22.1)
Overall survival – mo
 Median 57.3 45.5 85.2
(95% CI) (45.6–69.0) (34.9–56.1) (56.5–113.9)
Best response – no. (%)
 Complete response 7 (5.1%) 3 (3.8%) 7 (12.3%)
 Partial response 29 (21.2%) 18 (23.1%) 39 (68.4%)
 Stable disease 51 (37.2%) 24 (30.8%) 9 (15.8%)
 Progressive disease 50 (36.5%) 33 (42.3%) 2 (3.5%)
Complete or partial response
 No. of patients (%) 36 (26.3%) 21 (26.9%) 46 (80.7%)
(95% CI) (18.9–33.6) (17.6–36.7) (70.4–90.9)
  1. 95% CI 95% confidence interval. All treatments were begun prior to disease progression